A federal judge signaled Tuesday he would approve a $290 million settlement reached by Pershing Square Capital Management, Valeant Pharmaceuticals International Inc. and the shareholders of Allergan PLC who had alleged the two firms improperly profited from their failed attempt to buy the maker of Botox.
In a hearing Tuesday, the judge also said he intended to publicly issue a final version of a tentative opinion he had privately issued last month that rejected two key legal arguments Pershing Square and Valeant had made.... 